ArticleFrontiers in oncology2026

Case Report: Dramatic response of trastuzumab rezetecan in an NSCLC patient with EGFR sensitive mutation and primary ERBB2 genetic alterations.

Lin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.